Stockscreener 앱 받기
2.35
11.90%
0.25
시장 영업 전:
2.37
0.02
+0.85%
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - Yahoo Finance
CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus
CytomX Therapeutics files $250M mixed securities shelf - AInvest
CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest
CytomX Therapeutics beats Q2 revenue estimates - MarketScreener
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | CTMX Stock News - GuruFocus
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
CytomX Therapeutics to Report Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Oppenheimer Initiates Coverage on CytomX Therapeutics (NASDAQ:CTMX) - MarketBeat
What are the technical indicators suggesting about CytomX Therapeutics Inc.Explosive earning power - Jammu Links News
Is CytomX Therapeutics Inc. a good long term investmentGame-changing returns - Jammu Links News
How volatile is CytomX Therapeutics Inc. stock compared to the marketGame-changing capital returns - Jammu Links News
CytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last year - Yahoo Finance
Why is CytomX Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market trends with confidence - Jammu Links News
What institutional investors are buying CytomX Therapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
What is the risk reward ratio of investing in CytomX Therapeutics Inc. stockCapitalize on market trends before they peak - Jammu Links News
Does CytomX Therapeutics Inc. stock perform well during market downturnsFree Capital Growth Strategies - Jammu Links News
What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsInvest smarter with data-backed trading alerts - Jammu Links News
What are the latest earnings results for CytomX Therapeutics Inc.Overwhelming financial success - Jammu Links News
What is CytomX Therapeutics Inc. company’s growth strategyRapid capital growth - Jammu Links News
What makes CytomX Therapeutics Inc. stock price move sharplyFree Trading Psychology Coaching - Jammu Links News
How strong is CytomX Therapeutics Inc. company’s balance sheetMaximize returns with effective portfolio management - Jammu Links News
CytomX Therapeutics Inc.’s Price Action Aligns with Quant SignalsSwing Trading Entry Signals Suggest Opportunity Zone - metal.it
Should I hold or sell CytomX Therapeutics Inc. stock in 2025Swing Trade Review With Proven Results - jammulinksnews.com
CytomX Therapeutics' CX-2051 Shows Promising Results in Colorectal Cancer Treatment: Oppenheimer Analyst Initiates Coverage with Outperform Rating - AInvest
Lexeo Therapeutics Analyst Begins Coverage on Bullish Note; Top 3 Initiations for Thursday - AInvest
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 | CTMX Stock News - GuruFocus
CytomX Therapeutics: Oppenheimer initiates coverage with Outperform rating, PT $7. - AInvest
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - The Manila Times
CytomX Therapeutics Sets Q2 Earnings Date: Biotech Leader to Update on Masked Biologics Progress - Stock Titan
Oppenheimer initiates CytomX Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
How does CytomX Therapeutics Inc. compare to its industry peersEntry Signal Report For Beginners - Jammu Links News
Will CytomX Therapeutics Inc. stock recover after recent dropFast Gaining Stock Screener Reports Released - metal.it
0.24%
3.39%
자본화:
|
볼륨(24시간):